HDFC Pharma and Healthcare Fund
HDFC Mutual Fund · Sectoral/Thematic · Direct plan, growth option
| Period | Scheme | Category median | Healthcare & pharma median |
|---|---|---|---|
| 1 month | -2.0% | -5.4% | -3.1% |
| 3 months | 4.5% | -2.8% | 3.0% |
| 6 months | 26.0% | 8.9% | 21.7% |
| Year to date | 24.1% | -2.0% | 17.3% |
| 1 year | 26.6% | 1.4% | 17.5% |
| 3 years (CAGR) | 30.2% | 13.0% | 20.8% |
| 5 years (CAGR) | n/a | 12.0% | 15.3% |
| 7 years (CAGR) | n/a | 17.0% | 24.9% |
| 10 years (CAGR) | n/a | 14.6% | 14.7% |
| Since first NAV (CAGR) | 30.3% | – | – |
“Healthcare & pharma” is MFIC's grouping of Sectoral/Thematic schemes by the theme or index in their names, not an AMFI category.
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | 23.2% | 11.8% |
| 3Y rolling median | n/a | 17.5% |
| 3Y rolling worst | n/a | 3.0% |
| 3Y periods positive | n/a | 100% |
| 3Y periods ahead of benchmark | n/a | 84% |
| 5Y rolling median | n/a | 15.6% |
| 5Y rolling worst | n/a | 1.8% |
| 5Y periods ahead of benchmark | n/a | 91% |
Benchmark: Nifty 500 (proxy: Motilal Oswal Nifty 500 Index Fund, price return).
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | 16.1% | 16.7% |
| Sharpe ratio | 1.50 | 0.42 |
| Sortino ratio | 2.86 | 0.63 |
| Beta | 0.72 | 0.96 |
| Alpha (ann.) | 21.7% | 3.7% |
| Upside capture | 136.86 | 106.94 |
| Downside capture | 41.95 | 95.17 |
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | −14.9% | −23.1% |
| Maximum drawdown, last 10Y | n/a | −38.3% |
| Maximum drawdown, last 5Y | n/a | −22.3% |
| Current drawdown | −4.0% | −8.3% |
| Recovery time of worst fall | 126 days | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), Direct plan | n/a | 1.23% |
| AUM, whole scheme (₹ crore) | 3,501 | 1,272 |
| Riskometer | Very High | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
| Measure | Scheme | Benchmark / category |
|---|---|---|
| Return, 1 year (AMFI) | 27.8% | 16.8% TRI |
Official benchmark: BSE Healthcare TRI (total return index, as published by AMFI). Category consistency: last 10 years of month-ends, Sectoral/Thematic Direct plans; how it is calculated.
| Year | Scheme | Nifty 500 proxy | Difference |
|---|---|---|---|
| 2026 YTD | 24.1% | -7.8% | +31.9% |
| 2025 | 2.4% | 7.7% | −5.3% |
| 2024 | 52.2% | 15.6% | +36.6% |
Benchmark proxy: Motilal Oswal Nifty 500 Index Fund (Direct plan NAV, price return), which carries its own costs. The first year starts from the first 31 December in the scheme's history.
| Period | Invested | Value | XIRR |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,40,146 | 32.5% |
Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.
| Scheme | Category | Correlation | 3Y CAGR |
|---|---|---|---|
| UTI - Healthcare Fund | Sectoral/Thematic | 0.98 | 22.5% |
| WhiteOak Capital Pharma and Healthcare Fund | Sectoral/Thematic | 0.98 | n/a |
| Mirae Asset Healthcare Fund | Sectoral/Thematic | 0.98 | 21.8% |
| LIC MF Healthcare Fund | Sectoral/Thematic | 0.97 | 20.9% |
| ITI Pharma and Healthcare Fund | Sectoral/Thematic | 0.97 | 18.9% |
| Kotak Healthcare Fund | Sectoral/Thematic | 0.97 | n/a |
- What is the latest NAV of HDFC Pharma and Healthcare Fund?
- The NAV of the Direct plan (growth option) was ₹21.9790 on 2 Oct 2026, as published by AMFI.
- Which category is HDFC Pharma and Healthcare Fund in?
- It is classified as Sectoral/Thematic in AMFI's daily NAV file; a Sectoral/Thematic scheme invests at least 80% in one sector or theme. MFIC compares it with 253 Sectoral/Thematic schemes (Direct plans).
- What returns has HDFC Pharma and Healthcare Fund delivered?
- Over one year the NAV changed by 26.6%. The 3-year CAGR is 30.2% (category median 13.0%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
- What was the largest fall in HDFC Pharma and Healthcare Fund's NAV?
- The largest peak-to-trough fall in its available history was 14.9%.
- How volatile is HDFC Pharma and Healthcare Fund?
- Its annualised standard deviation of monthly returns over the last 36 months is 16.1%, which is below the Sectoral/Thematic category median of 16.7%.
- How large is HDFC Pharma and Healthcare Fund?
- Assets under management of the whole scheme were ₹3,501 crore on 30 Sep 2026, as published by AMFI.
- What is the riskometer level of HDFC Pharma and Healthcare Fund?
- AMFI lists the scheme's riskometer as “Very High”, and its benchmark's as “Very High”. The riskometer is a label of potential risk set under SEBI rules, not a forecast.
- What is the difference between the Direct and Regular plans?
- Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 26.6% and the Regular plan's by 25.2%. The Regular plan includes the services of a distributor.
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.